Scroll Top
Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles
Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles

Home » Newsroom » Page 2

Perspectives from Gain Therapeutics Perspectives from Gain Therapeutics
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles
By Admin Roshan

07 Oct: Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective Effect in GBA1-Parkinson’s Disease Models …

Read more

Read More
By Admin Roshan

03 Oct: Gain Therapeutics to Participate at Upcoming Investor Conferences

BETHESDA, Md., Oct. 03, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

30 Sep: Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

GT-02287 Increases Peripheral GCase Activity GT-02287 Demonstrates CNS Exposure Company to Host Webinar to Discuss Results at 8:30 AM ET Today BETHESDA, Md., Sept. 30, …

Read more

Read More
By Admin Roshan

26 Sep: Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients Event Will Be …

Read more

Read More
By Admin Roshan

19 Sep: Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

03 Sep: Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

29 Aug: Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial in Patients in …

Read more

Read More
By Admin Roshan

08 Aug: Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 …

Read more

Read More
By Admin Roshan

01 Aug: Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery …

Read more

Read More
By Admin Roshan

09 Jul: Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease

GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate …

Read more

Read More
By Admin Roshan

28 Jun: Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

27 Jun: Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, …

Read more

Read More
By Admin Roshan

27 Jun: Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits BETHESDA, Md., June 27, 2024 (GLOBE …

Read more

Read More
By Admin Roshan

25 Jun: Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

13 Jun: Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering …

Read more

Read More
By Admin Roshan

13 Jun: Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and …

Read more

Read More
By Admin Roshan

30 May: Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease BETHESDA, Md., May 30, 2024 (GLOBE NEWSWIRE) …

Read more

Read More
By Admin Roshan

14 May: Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

24 Apr: Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

08 Apr: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

01 Apr: Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

26 Mar: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

15 Mar: Gain Therapeutics to Present at Public Ventures Discovery Day

Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment …

Read more

Read More
By Admin Roshan

05 Mar: Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction BETHESDA, Md., March 05, 2024 …

Read more

Read More
By Admin Roshan

27 Feb: Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and …

Read more

Read More
By Admin Roshan

14 Feb: Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST BETHESDA, …

Read more

Read More
By Admin Roshan

06 Feb: UPDATE – Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm BETHESDA, Md., …

Read more

Read More
By Admin Roshan

06 Feb: Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm BETHESDA, Md., …

Read more

Read More
By Admin Roshan

31 Jan: Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain,” or the “Company”), a biotechnology company leading the discovery and development …

Read more

Read More
By Admin Roshan

02 Jan: Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease BETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: …

Read more

Read More
1 2 3 … 6
About Us
  • Overview
  • Leadership Team
  • Board of Directors
  • Scientific Advisory Board
  • Partners
  • Careers
Science & Technology
  • Platform Technology
  • Science
  • Posters
  • Publications
INVESTORS & MEDIA
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Investor Resources
  • SEC Filings
  • Governance Documents
  • 2024 Gain Therapeutics, Inc.
Linkedin-in Twitter Youtube
  • ©2023 Gain Therapeutics, Inc.
  • Pipeline
  • Perspectives
  • Contact Us
  • Sign up
Linkedin-in Twitter Youtube
  • About us
    • Overview
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Partners
    • Careers
  • Science and Technology
    • Platform Technology
    • Science
    • Posters
    • Publications
  • Pipeline
  • Investors & Media
    • Overview
    • News & Events
    • Stock Information
    • Analyst Coverage
    • Investor Resources
    • SEC Filings
    • Governance Documents
  • Contact Us
  • Perspectives
    • Events and Team Interviews
    • Parkinson 101
    • Technical Articles